

Some things you always wanted
to know about clinical trials but
were afraid to ask

Peter A. Lachenbruch

Division of Biostatistics, CBER

The views are not necessarily an
official position of the FDA

What are Phase 1, 2, 3, and 4 trials?

- Phase 1 - first trial in humans
 - Designed to estimate a maximum tolerated dose.
 - Small number of patients (3 to 10 per dose)
 - Total number of patients typically fewer than 50
 - Usually dose escalation: work from a low dose to a higher one, until toxicity is observed
 - Estimate toxicity as a function of dose (or $\log(\text{dose})$)

Phase 2

- Phase 2 studies evaluate biologic activity and adverse event rates
 - Determine adequate response rate (e.g., at least 20% of patients will respond)
 - Find the right dose / schedule
 - Serum levels of drug?
 - Trough levels
 - Generally fewer than 100 patients

Phase 2 (2)

- Preliminary ideas on adverse event rates - since studies are small, estimates of rates are imprecise
 - Standard deviation proportional to $1/\sqrt{n}$
 - Studies usually not comparative, so don't know if the rate is too high, or just characteristic of the disease

Phase 3

- **Comparative** trial to evaluate drug
 - Comparator group important - Standard of care, Placebo, never nothing in serious or life-threatening diseases (ICH E3, E9, E10)
 - Endpoint - must be clinically relevant to disease (e.g., reduce mortality, reinfarction, agreed on criteria such as ACR20, etc.)
 - Should be validated as relevant in the disease

Phase 3 (2)

- Sample size depends on level of type I error, type II error, variability of response, anticipated difference between treatment and control
- Use of subgroups (strata) may make comparison more precise
- Analysis plan must be specified *a priori*

Phase 4

- Post-marketing surveillance
 - Mostly Passive reporting
 - Subject to biases
 - Sometimes FDA will require an epidemiological study post-marketing (e.g., Varivax or Carticel)

How is the patient enrollment size determined for each site?

- History at the site for diagnosing patients for the specific disease (for conditions matching those in the trial) - e.g., a stage 3 cancer trial might not be easily conducted in a rural primary care setting
- Randomize within site, so don't want sites with very few patients
- Also may stratify by prognostic factors (sex, age, stage of disease)

What if site doesn't meet enrollment targets?

- Study may need to add additional sites to reach sample size goals
- Possibility of imbalance in the randomization
- Future studies may decide not to use the under enrolling site

How does sponsor combine data from multiple sites?

- Statistical models must account for possible differences in the sites (e.g., different care patterns, etc.), as well as other strata
 - This is called stratification or blocking. Statistical methods are well-developed for this
 - Subtract the mean of the response at the site from all measurements. This aligns the adjusted response.

Combining data across sites

- Potential problem:
 - If sites have different responses to treatment (called a treatment by site interaction), we have a problem
 - In one study, one site had a large positive treatment effect, while three others showed no difference. Led to discovery of other problems
- For global trials, the situation is essentially the same

What data will be included in the licensing application?

- Study reports that will comprise the submission (phase 1, 2, 3 studies) need to be submitted.
 - Negotiate with FDA regarding early phase studies
 - All phase 3 studies will be required - can't just show 2 positive studies and ignore 10 negative ones

Data in marketing application

- Need to show all efficacy data from primary, secondary, and tertiary endpoints
 - If a composite endpoint is used, it's useful to include the components of the composite.
- Safety data
 - All AEs include mild, moderate, severe, deaths
 - If product is a member of a known class, some events are expected and won't be a problem unless they are excessive

Marketing application information

- Include the final revision of the protocol
 - Should be dated before the data are unblinded
 - Non-protocol analyses will be considered exploratory and may be useful for labeling, but not for showing an indication

Who decides on the CRF fields?

Why fill in all the fields?

- Usually decided by clinicians from the sponsor with input from FDA clinicians
- Need all fields completed to show that the information was sought (either by question or lab test) and negative, or not done. A blank field does not distinguish.

If a patient leaves the trial, does their data still count?

- Data always count - intention-to-treat means that these patients should be followed, if possible.
- Excluding such patients means that the patients who do poorest won't affect the study - not a good idea

Define some statistical terms

- Blinding (double) - means that neither the patient nor the evaluator knows what treatment has been given. Very important when subjective endpoints are involved.
 - Not always possible if different schedules or side effects of drugs are characteristic of treatments

Definitions (2)

- Randomization - ensures that patients are given treatment in such a way that no investigator bias is involved. There must be no way the study personnel know what treatment the next patient will receive.
 - When this principle has been violated, studies have been discounted and had to be repeated.

Definitions (3)

- Adequate and Well-controlled study - this refers to the way the study has been conducted:
 - Was it randomized?
 - Was it blinded if possible?
 - Was the control group appropriate?
 - Patients comparable at baseline?
 - Control treatments given at labeled levels?

Definitions (4)

- Control groups (ICH E10) are a crucial part of a trial.
 - FDA expects that the patient population will be split into new treatment and “not new treatment” groups
 - Concurrent placebo control - compares standard of care + placebo with standard of care + active treatment

Definitions (5)

- Controls (continued)
 - Concurrent no-treatment control - compares no treatment group with active treatment group (may not be ethical in all cases) and is difficult to blind
 - Concurrent active control - compares active control with treatment - may wish to show non-inferiority

Definitions (6)

- Historical control
 - only in unusual circumstances - lack of concurrency, possible different entry criteria,
 - Patients may not be comparable

How does coding aid the analysis?

- I prefer to have raw data submitted to the sponsor and they code it later rather than have sites do it
 - Consistency in coding
 - Possible to retrieve the underlying data
 - Text coding may be useful to retrieve common problems that arise

What do you do with comment fields and unsolicited text?

- These are used mostly for safety analyses by clinical reviewers.
 - If there are repeated comments at many sites, they may be encoded and analyzed
 - Sponsor may audit records at sites to determine if some “unsolicited events” are really more common

How are protocol/trial considerations determined?

- The indication the sponsor wants tends to be the main determinant. FDA will sometimes differ with what the right endpoint is, what the right trial is, etc.
- The size and duration of the treatment effect will determine sample size, number of sites, and duration of follow up, etc.

Why can't we vary from the protocol?

- It opens the door to fraudulent practice
 - Sponsor and investigator have agreed to do a certain trial and deviations from that are not allowed
- If protocol isn't followed, we have no idea what the trial has shown - some sites may have admitted one sort of patient, others another; some may deliver one sort of treatment, others another

Why follow protocol? (2)

- FDA will not accept trials with many protocol deviations
 - Require sponsor to redo the trial
- If small number of deviations relative to the sample size, usually not a problem, but large numbers suggest systematic issues and can get an investigator disbarred
- “Almost eligible” is still a violation - don't do it

How do statisticians contribute to the regulatory review?

- They review the data analyses and replicate major analyses
- Ensure that proper analyses were done
- Do new exploratory analyses (useful for labeling, or checking unexpected outcomes)
- Check data for usability

What is expected of investigators and monitors?

- Carry out the protocol exactly
- Submit data that are internally consistent
 - Proper links among files
 - Values lie within appropriate ranges
 - Reduce missing values to a minimum (follow patients after dropout, etc.)
 - Don't falsify any data - if discovered, all data from the site may be discarded

When/why does a sponsor perform an interim analysis?

- Why?

- Stop early for a safety problem
- Stop early because drug doesn't work
- Stop early because drug works

- When?

- Timed by fraction of patients enrolled, fraction of events observed

Interim analysis (2)

- Plan analyses

- State number (usually not too many, ≤ 5)
- Ensure that blindness is maintained (DSMB usually needed)
- Adjust significance levels (O'Brien-Fleming, Haybittle-Peto, Pocock, Bonferroni)

Break blind if patient has AE?

- Yes - should do for patient's safety, especially if a serious AE has occurred
- Patient is usually removed from the study and treated as a failure
- Because blind is broken in these cases, it's important that treatments be indistinguishable - should look alike, smell alike, etc.

How does FDA decide what goes on product label?

- The results of all the trials go into the product label. The FDA gives the interpretation.
 - Advertising and promotion are major issues, so the wording of the label is key
- AEs are usually listed in decreasing order of frequency, but not below a given percent (may vary depending on product and trial experience)

Finale

- These comments give a brief introduction to regulatory aspects of clinical trials
- Further information available at
 - www.fda.gov - has guidance documents with a lot of information on regulations, requirements
 - www.ich.org - provides International Conference on Harmonization documents; see E3, E9, E10 for material on clinical trials